GE Healthcare float sunk in favour of Danaher deal
GE sells its Biopharma business for $21.4bn, but is its IPO cancelled or merely on hold?
Auris acquisition could prompt more mega VC rounds
The J&J-Auris tie-up will yield a huge return for investors who went in big.
J&J’s Auris buy looks like a Verb swerve
Johnson & Johnson’s $3.4bn move for the robotic surgery specialist Auris Health could be bad news for its Verb Surgical joint venture.
Novo Nordisk sticks its neck out for a tech that promises oral insulin
A capsule device inspired by the shape of a tortoise’s shell might just be able to deliver proteins orally, and Novo Nordisk is on board. But the tech is still years away…
Oncocyte banks on a new kind of liquid biopsy
The Biotime-backed group believes it can use immune system gene expression levels to detect lung cancer earlier. But another trial will be necessary before the test can…
Deals galore for a new generation of transcatheter mitral valves
Transcatheter mitral valve replacement is wrenching the spotlight away from the repair devices that grabbed the headlines last summer.
Approvals of high-risk devices drop as de novos take off
Changes at the FDA have altered the device approval landscape, with the de novo route now the most popular.
Medtech IPOs rocketed just as stock markets faltered
The value of listings hit a new quarterly high courtesy of Guardant and Axonics.
Carmat’s heart sinks with another delay
Despite encouraging interim pivotal data, Carmat’s artificial heart seems as far from market as ever.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.